Top of this page
Skip navigation, go straight to the content

Our Science UCB0942

Padsevonil (UCB0942)

Disease area
studied
Abbreviated title Phase Study ID Registry database Study results Lay summary Publication (if available)
Epilepsy Double-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety/Tolerability, and Pharmacokinetic Profile of UCB0942 in Adults With Highly Drug-resistant Focal Epilepsy. Phase 2 EP0069
Completed
NCT02495844
2014-003330-12

LINK
Muglia P. et al. [abstract 1.283] available on Annual Meeting Abstract Database www.aesnet.org
Epilepsy An open-label, multicenter, extension study to evaluate the long-term safety, tolerability, and efficacy of UCB0942 when used as adjunctive therapy for partial-onset seizures in adult subjects with highly drug-resistant focal epilepsy
 
Phase 2 EP0073
Ongoing
NCT02625090
2015-001268-20
Epilepsy The purpose of the study is to characterize the dose-response relationship with respect to efficacy of Padsevonil administered concomitantly with up to 3 anti-epileptic drugs (AEDs) for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy Phase 2 EP0091 
Ongoing
NCT03373383 
 Epilepsy Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy Phase 2 EP0093
Ongoing
NCT03370120